MY ACCOUNT | NEWSLETTER |

ReGum scientifically proven to heal gum recession

New technology successfully treats periodontitis in dogs


Israeli startup BioChange has developed a breakthrough technology for tissue regeneration. This new technology, known as ReGum, was found to successfully treat periodontitis — gum recession disease — in dogs. 

ReGum led to a 100% improvement in comparison to the standard-of-care treatment regimen, with a significant regeneration of periodontal tissue including gum and bone tissues, according to a BioChange news release. The statistically significant findings were recently published in Frontiers in Veterinary Science.  

Dr. Ana Nemec, principal investigator of the study and veterinary faculty at the University of Ljubljana in Slovenia, said the addition of this new product during professional treatment by a veterinarian can make a significant difference, saving more teeth from extraction. Co-authors include first author Dr. Jerzy Pawel Gawor from veterinary clinic Arka in Krakow, Poland, and Dr. Peter Strøm of Specialistdyrehospitalet in Denmark. 

Ishay Attar, BioChange founder and CEO, said that Dr. Nemec’s research began as an important exploration of the startup’s regenerative scaffold technology platform and eventually led to these results.  

"We were able to regenerate the complex periodontal tissue, which is made up of four different tissue types that support the tooth," he said. "No other product has been able to achieve such results in terms of safety and effectiveness." 

Periodontal disease is a common ailment in both dogs and people and effective treatments are needed, according to BioChange.  

The technology is being developed currently for veterinary use and ultimately is also planned to be available for human use. BioChange expects regulatory approval for use in people within the next couple of years. About 40% of human adults are estimated to have some effect from periodontitis and gum recession. 

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Clinical outcomes and association with disease progression and survival of subclinical bacteriuria in cats with chronic kidney disease: a multicenter retrospective study.

Like0
Dislike1

Treatment of Canine Pemphigus Foliaceus, Pemphigus Vulgaris and Mucous Membrane Pemphigoid With Oclacitinib: A Retrospective Analysis of 21 Cases.

Like0
Dislike1

A Systematic Review and Meta-Analysis on the Global Seroprevalence of Porcine Reproductive and Respiratory Virus (PRRSV) in Pigs and Wild Boars: A Widespread and Impactful Swine Virus.

Like0
Dislike1

WSU seeks to curb deadly pneumonia threatening bighorn sheep recovery

Like0
Dislike1

Pet Insurance Market Could Exceed USD 113.7 Billion by 2035, as Rising Veterinary Costs and Expanding Insurance Penetration

Like0
Dislike1

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top